Compare iShares MSCI Singapore ETF (EWS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs GSK plc — how do they compare? iShares MSCI Singapore ETF trades at $33.82, while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| EWS | GSK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $33.92 | $61.18 |
52-Week Low | $26.71 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $33.64, up 1.42% and hitting a new 52-week high. Technical indicators show a bullish moving average trend but overbought oscillators. The ETF benefits from Singapore's economic resilience, AI-driven growth, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026.
Outlook is positive due to strong momentum and structural growth in Singapore's financial and tech sectors. Risks include concentrated exposure to financials (54% of holdings) and sensitivity to Asian market volatility. The ETF offers diversification but requires monitoring for overextension near all-time highs.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
